-
公开(公告)号：US20210163586A1
公开(公告)日：2021-06-03
申请号：US17172109
申请日：2021-02-10
Applicant: UCB BIOPHARMA SRL
Inventor： NEESHA DEDI , BREDA TWOMEY , MICHAEL JOHN WRIGHT , GARETH DAVIES , DAVID JAMES MCMILLAN
Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
-
公开(公告)号：US20240076365A1
公开(公告)日：2024-03-07
申请号：US18502188
申请日：2023-11-06
Applicant: UCB BIOPHARMA SRL
Inventor： NEESHA DEDI , BREDA TWOMEY , MICHAEL JOHN WRIGHT , GARETH CHARLES GLYNDWR DAVIES , DAVID JAMES MCMILLAN
CPC classification number: C07K16/22 , A61P9/12 , C07K14/51 , G01N33/6854 , A61K2039/505
Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
-
公开(公告)号：US20230416350A1
公开(公告)日：2023-12-28
申请号：US18344945
申请日：2023-06-30
Applicant: UCB BIOPHARMA SRL
Inventor： DAVID EDWARD ORMONDE KNIGHT , TERENCE SEWARD BAKER , DAVID JAMES MCMILLAN , ROBERT ANTHONY GRIFFIN , GEORGES MAIRET-COELLO , PATRICK DOWNEY , JEAN-PHILIPPE COURADE
CPC classification number: C07K16/18 , C07K14/4711 , A61P25/28 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/70
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
公开(公告)号：US20210115121A1
公开(公告)日：2021-04-22
申请号：US17136189
申请日：2020-12-29
Applicant: UCB BIOPHARMA SRL
Inventor： DAVID EDWARD ORMONDE KNIGHT , TERENCE SEWARD BAKER , DAVID JAMES MCMILLAN , ROBERT ANTHONY GRIFFIN , GEORGES MAIRET-COELLO , PATRICK DOWNEY , JEAN-PHILIPPE COURADE
Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
-
公开(公告)号：BR112020010508A2
公开(公告)日：2020-11-24
申请号：BR112020010508
申请日：2018-12-13
Applicant: UCB BIOPHARMA SRL
Inventor： DANIEL JOHN LIGHTWOOD , DAVID JAMES MCMILLAN , KERRY LOUISE TYSON , LORENZO DE LICHTERVELDE , MARCO KRIEK , PATRICK DOWNEY , PETER CHARLES ELLIOTT , TERENCE SEWARD BAKER
IPC: A61K39/395 , A61K39/00 , A61P25/16 , A61P25/28 , C07K16/28
Abstract: a presente invenção se refere a anticorpos de ligação à alfa-sinucleína e fragmentos dos mesmos, capazes de se ligarem à alfa-sinucleína como um monômero e em fibrilas e previnem a agregação de alfa-sinucleína induzida por fibrilas de alfa-sinucleína. os anticorpos da presente invenção são para uso no tratamento de alfa-sinucleinopatias, incluindo a doença de parkinson.
-
Patent Agency Ranking
公开(公告)号：CL2024003722A1
公开(公告)日：2025-01-31
申请号：CL2024003722
申请日：2024-12-04
Applicant: UCB BIOPHARMA SRL
Inventor： JAMES ROBERT CHAVES BIRTLEY , LARA KEVORKIAN , DAVID JAMES MCMILLAN
Abstract: La invención se refiere al campo de las proteínas de fusión y, en particular, a las proteínas de fusión que comprenden un resto de folistatina. La invención también se refiere a métodos de fabricación de dichas proteínas de fusión, junto con formulaciones farmacéuticas que comprenden dichas proteínas de fusión.
-
公开(公告)号：BR112020010504A2
公开(公告)日：2020-11-24
申请号：BR112020010504
申请日：2018-12-13
Applicant: UCB BIOPHARMA SRL
Inventor： DANIEL JOHN LIGHTWOOD , DAVID JAMES MCMILLAN , KERRY LOUISE TYSON , LORENZO DE LICHTERVELDE , PATRICK DOWNEY , RALPH ADAMS , TERENCE SEWARD BAKER
IPC: C07K16/18
Abstract: a presente invenção se refere a anticorpos que se ligam à alfa-sinucleína e fragmentos dos mesmos capazes de se ligar à alfa-sinucleína como monômero e em fibrilas e impedem a agregação de alfa-sinucleína induzida por fibrilas de alfa-sinucleína. os anticorpos da presente invenção são para uso no tratamento de alfa-sinucleinopatias, incluindo a doença de parkinson.
-
公开(公告)号：BR112022015281A2
公开(公告)日：2022-09-20
申请号：BR112022015281
申请日：2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor： NEESHA DEDI , PETER CHARLES ELLIOTT , SEPPE FRANS ROMAN LEYSEN , SEAN MASON , DAVID JAMES MCMILLAN , GILLIAN CLAIRE NESS , NICCOLO PENGO , MARTIN ANTHONY REDHEAD , ALISON TURNER , KERRY LOUISE TYSON
Abstract: ANTICORPOS CONTRA KLK5. A presente invenção se refere a anticorpos que ligam e inibem KLK5 e métodos de usar os mesmos para tratar doenças causadas pelo desequilíbrio de KLK5. Em particular, a presente invenção se refere a anticorpos inibidores da ligação de KLK5 e seu uso no tratamento da doença de Netherton, dermatite atópica e câncer.
-
公开(公告)号：BR112022015279A2
公开(公告)日：2022-09-20
申请号：BR112022015279
申请日：2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor： NEESHA DEDI , PETER CHARLES ELLIOTT , SEPPE FRANS ROMAN LEYSEN , SEAN MASON , DAVID JAMES MCMILLAN , GILLIAN CLAIRE NESS , NICCOLO PENGO , MARTIN ANTHONY REDHEAD , ALISON TURNER , KERRY LOUISE TYSON
Abstract: ANTICORPOS CONTRA KLK5. A presente invenção se refere a anticorpos que ligam e inibem KLK5 e métodos de usar os mesmos para tratar doenças causadas pelo desequilíbrio de KLK5. Em particular, a presente invenção se refere a anticorpos inibidores da ligação de KLK5 e seu uso no tratamento da doença de Netherton, dermatite atópica e câncer.
-
公开(公告)号：ZA202003414B
公开(公告)日：2022-03-30
申请号：ZA202003414
申请日：2020-06-08
Applicant: UCB BIOPHARMA SRL
Inventor： PATRICK DOWNEY , KERRY LOUISE TYSON , MARCO KRIEK , LORENZO DE LICHTERVELDE , DANIEL JOHN LIGHTWOOD , DAVID JAMES MCMILLAN , PETER CHARLES ELLIOTT , TERENCE SEWARD BAKER
Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.025 seconds)
